Life sciences tools Life Sciences Solutions organic revenue growth measures segment revenue growth after excluding acquisitions, divestitures, and currency translation under Thermo Fisher Scientific's non-GAAP methodology.
Thermo Fisher reported 3% organic revenue growth in Life Sciences Solutions for the second quarter of 2026. Segment revenue rose to $2.815B from $2.499B.
Acquisitions made reported growth much faster
Reported revenue increased 13%, including a 9% acquisition and divestiture effect and a 1% currency contribution.
Thermo Fisher said the organic increase was primarily driven by bioproduction.
Organic growth separates underlying operations from portfolio change
The measure is useful when acquisitions materially alter the segment's reported growth rate, but it remains Thermo Fisher's issuer-defined non-GAAP calculation.
Pair it with bioproduction reported revenue growth contribution and Life Sciences Solutions segment income margin.
Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.
Part of the Life Sciences Tools & Biopharma Services Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- TMOOpen operating-model research →10 of 10 reviewed concepts in Life Sciences Tools & Biopharma Services EconomicsOrganic segment growth4 of 4 bridge concepts supportedContinue through this bridge:Analytical Instruments Organic GrowthLab Products & Biopharma Organic GrowthSpecialty Diagnostics Organic Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare Life Sciences Solutions organic growth
Compare underlying Life Sciences Solutions growth separately from acquisition, divestiture, and currency effects.
Explore more topics in the Financial Research Encyclopedia.